Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMOR phase 3 study of Aramchol in nonalcoholic steatohepatitis
MOH_2020-11-04_009452Phase 3Not yet recruiting
- Sponsor
- Galmed Pharmaceuticals
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aramchol in metabolic dysfunction-associated steatohepatitis (MASH) (3 cohorts), sponsored by Galmed Pharmaceuticals. Primary endpoints: NASH resolution, Fibrosis improvement and 1 more. Planned start May 2021; status: not yet recruiting.
02
Drugs
aramchol
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2020-11-04_009452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-04_009452.